The alliance is focusing initially on two disease areas – type 1 diabetes and inflammatory bowel disease – and revolves around Quell’s T-regulatory (Treg) cell platform, an area of ...

HOUSTON, April 22, 2025 /PRNewswire/ -- New findings published today in NEJM Evidence reveal promising clinical outcome for Cellenkos Inc.'s cryopreserved, allogeneic, T regulatory (Treg ...